Evercore ISI Forecasts Strong Price Appreciation for BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock

BioCryst Pharmaceuticals (NASDAQ:BCRX) had its price target raised by stock analysts at Evercore ISI from $10.00 to $12.00 in a research note issued on Monday,Benzinga reports. The firm presently has an “outperform” rating on the biotechnology company’s stock. Evercore ISI’s price target indicates a potential upside of 65.98% from the company’s previous close.

Several other analysts have also issued reports on the stock. Barclays increased their price target on shares of BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the stock an “equal weight” rating in a research report on Tuesday, November 5th. Royal Bank of Canada restated an “outperform” rating and set a $10.00 target price on shares of BioCryst Pharmaceuticals in a research note on Tuesday, November 5th. Finally, Needham & Company LLC lifted their price target on BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the company a “buy” rating in a research note on Monday. One analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $15.17.

BioCryst Pharmaceuticals Price Performance

BioCryst Pharmaceuticals stock opened at $7.23 on Monday. The firm has a market cap of $1.50 billion, a PE ratio of -11.85 and a beta of 1.76. The stock’s fifty day moving average price is $7.60 and its two-hundred day moving average price is $7.60. BioCryst Pharmaceuticals has a one year low of $4.03 and a one year high of $8.88.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its quarterly earnings results on Monday, November 4th. The biotechnology company reported ($0.07) EPS for the quarter, hitting analysts’ consensus estimates of ($0.07). The company had revenue of $117.10 million during the quarter, compared to the consensus estimate of $113.99 million. During the same quarter in the previous year, the business posted ($0.19) EPS. The firm’s revenue for the quarter was up 35.1% on a year-over-year basis. Sell-side analysts expect that BioCryst Pharmaceuticals will post -0.38 earnings per share for the current fiscal year.

Institutional Trading of BioCryst Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the stock. Deerfield Management Company L.P. Series C increased its holdings in shares of BioCryst Pharmaceuticals by 62.9% during the second quarter. Deerfield Management Company L.P. Series C now owns 8,135,804 shares of the biotechnology company’s stock worth $50,279,000 after buying an additional 3,140,804 shares in the last quarter. Geode Capital Management LLC grew its position in BioCryst Pharmaceuticals by 2.7% during the 3rd quarter. Geode Capital Management LLC now owns 4,837,985 shares of the biotechnology company’s stock worth $36,776,000 after acquiring an additional 127,708 shares during the last quarter. Fisher Asset Management LLC grew its position in BioCryst Pharmaceuticals by 16.9% during the 3rd quarter. Fisher Asset Management LLC now owns 3,338,062 shares of the biotechnology company’s stock worth $25,369,000 after acquiring an additional 481,359 shares during the last quarter. Two Sigma Advisers LP increased its holdings in BioCryst Pharmaceuticals by 13.6% in the 3rd quarter. Two Sigma Advisers LP now owns 2,181,012 shares of the biotechnology company’s stock worth $16,576,000 after purchasing an additional 261,500 shares in the last quarter. Finally, Rice Hall James & Associates LLC raised its position in BioCryst Pharmaceuticals by 4.0% in the third quarter. Rice Hall James & Associates LLC now owns 2,163,743 shares of the biotechnology company’s stock valued at $16,444,000 after purchasing an additional 84,102 shares during the last quarter. Institutional investors and hedge funds own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.